13 August 2021 |
Campaigning and research, IBTA
The International Brain Tumour Alliance (IBTA) is inviting people over the age of 18 who have been diagnosed with any type or grade of brain tumour to complete their most recent online survey.
It is gathering information on Covid-19 vaccines in relation to brain tumour patients including how the coronavirus vaccination programmes in different countries have been offered; Covid-19 testing; which vaccines brain tumour patients have received; and vaccine side effects.
You do not have to have received a Covid vaccine to contribute to this valuable survey, so if you have been diagnosed with a brain tumour (including metastatic brain tumours) please do take part. Data is collected anonymously and the survey typically takes no more than 15 minutes to complete. The deadline for submitting responses is 31st August 2021.
This survey is now closed.
The International Brain Tumour Alliance (IBTA) is a unique global network for brain tumour patients and carer groups around the world.
The IBTA work alongside and represents, members of our community – including researchers, scientists, clinicians, nurses and allied healthcare professionals – to engage in advocacy, raise awareness and share information.
#Covid19 #Coronavirus #braintumour
Tags: Covid-19, IBTA
2 July 2026
Our Head of Support Services and CEO shared the importance of timely, personalised support for people affected by a brain tumour. Brain Tumour Support was delighted to attend BNOS 2026 in Birmingham this week, joining healthcare professionals, researchers, charities and…
Read
16 June 2026
Brain Tumour Support has welcomed the powerful and emotive discussions that took place in Parliament yesterday (Monday 15 June), as the urgent need for greater investment in brain cancer research and treatment was debated. Securing this debate was a notable…
Read
21 May 2026
When someone is diagnosed with a brain tumour, they may be overwhelmed by the need to understand a new language. This article aims to provide a shortcut to that new language so that patients, caregivers, colleagues, employers, journalists, policymakers and…
Read
31 March 2026
At Brain Tumour Support, we have been closely following developments around Vorasidenib, a targeted therapy that has shown promise for people living with certain types of low-grade glioma. So we are delighted to share today’s final decision by the National…
Read